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Abstract
Cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) are defined as a small population of cancer cells that have self-
renewal ability, differentiation ability and high tumor-initiating ability. CSCs/CICs are resistant to cancer therapies including
chemotherapy and radiotherapy. Therefore, CSCs/CICs are thought to be responsible for cancer recurrence and distant
metastasis after treatment. However, the molecular mechanisms of CSCs/CICs are still elusive. In this study, we isolated
CSCs/CICs as side population (SP) cells from lung carcinoma, colon carcinoma and breast carcinoma cells and analyzed the
molecular mechanisms of CSCs/CICs. cDNA micro-array screening and RT-PCR analysis revealed that sperm mitochondria-
associated cysteine-rich protein (SMCP) is ectopically expressed in SP cells. 59-Rapid amplification of cDNA end (RACE)
analysis revealed that the SMCP transcript in SP cells was a variant form (termed vt2) which is composed from only one
exon. SMCP vt2 was detected in only cancer cells, whereas the wild-type (vt1) form of SMCP was expressed in the testis.
SMCP was shown to have a role in tumor initiation by SMCP overexpression and SMCP knockdown using siRNAs in lung
cancer cells. Taken together, the initiation results indicate that an ectopically expressed variant form of SMCP has a role in
tumor initiation of CSCs/CICs and that the variant form of SMCP might be a novel CSC/CIC marker and a potential and
promising target of CSC/CIC-targeting therapy.
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Introduction
Recent progress in cancer research has revealed that cancers are
composed of morphologically and phenotypically heterogenous
malignant transformed cells, and only a small population of cancer
cells have tumor-initiating ability when transplanted into immune-
deficient mice (cancer stem cell hypothesis) [1,2]. These cells with
high tumorigenicity are called cancer stem-like cells (CSCs)/
cancer-initiating cells (CICs). In subsequent works, CSCs/CICs
were shown to be resistant to chemotherapies and radiotherapies
[3,4]. Therefore, CSCs/CICs are thought to be responsible for
disease recurrence after treatments and for distant metastasis,
which make the prognosis poor. Thus, eradication of CSCs/CICs
is essential for curing cancer.
CSCs/CICs have been isolated by several methods [5],
including (1) use of cell surface markers such as CD44+CD242
[6], CD133+ [7,8] and CD166+ [9], (2) side population (SP)
analysis [10], (3) ALDEFLUOR assay [11], and (4) spheroid
culture [12]. Using these methods CSCs/CICs have been
successfully isolated from acute myeloid leukemia [13–15] breast
cancer [6], lung cancer [16], colon cancer [7,8,17], brain tumors
[10,18–21], prostate cancer [22–24], pancreas cancer [25,26],
liver cancer [27] and melanoma [28]. However, these markers are
merely surrogate markers, and sometimes the expression of CSC/
CIC markers did not indicate highly tumorigenic CSCs/CICs
[29,30]. Therefore, further investigations of CSC/CIC markers
and molecular mechanisms of CSC/CIC are needed for the
establishment of CSC/CIC targeting therapy.
In this study, we investigated molecular aspects of highly
tumorigenic SP cells derived from lung, colon and breast cancer
cells and found that a splicing variant form of sperm mitochon-
dria-associated cysteine-rich protein (SMCP), which is expressed in
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normal testis tissues, is ectopically expressed in SP cells and that
SMCP has a role in the tumor-initiating ability of SP cells. These
findings indicate that SMCP might be a novel CSC/CIC marker
and a potential target for CSC/CIC targeting therapy.
Materials and Methods
Ethics statement
Mice were maintained and experimented on in accordance with
the guidelines of and after approval by the Committee of Sapporo
Medical University School of Medicine, Animal Experimentation
Center under permit number 10-032. Any animal found
unhealthy or sick was promptly euthanized. All studies were
approved by Institutional Review Boards (IRB) of Kushiro City
General Hospital. We obtained written informed consent from all
patients according to the guidelines of the Declaration of Helsinki.
Tissue samples
All studies were approved by Institutional Review Boards (IRB)
of Kushiro City General Hospital. Three pairs of lung cancers and
adjacent non-neoplastic lung tissues were obtained from surgically
resected tissues removed at Kushiro City General Hospital. The
histological types of the three cancer tissues were: case #1 and 2,
adenocarcinoma; case #3 and 4, squamous cell carcinoma; and
case #5, large cell carcinoma.
Cell culture
Lung adenocarcinoma cell line LHK2 was established in our
laboratory [31]. Lung small cell carcinoma cell line Lc817 was
purchased from the Japanese Cancer Research Resources Bank
(Osaka, Japan). Human breast adenocarcinoma cell line MCF7,
human lung adenocarcinoma cell line A549 and human embry-
onal kidney cell line HEK293T were purchased from ATCC
(Manassas, VA, USA). Colon adenocarcinoma cell line SW480
[32] was a kind gift from Dr. K. Imai (Sapporo, Japan). These cell
lines were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) (SIGMA-ALDRICH, St. Louis, MO, USA) with 10%
heat-inactivated fetal bovine serum (FBS; MP Biomedicals, Irvine,
CA, USA) at 37uC in a humidified atmosphere containing 5%
CO2. The retrovirus packaging cell line PLAT-A was kindly
provided by Dr. T. Kitamura (Tokyo, Japan) [33]. PLAT-A was
maintained in DMEM containing 10% FBS, 1 mg/mL puromycin
(SIGMA-ALDRICH), and 10 mg/mL blasticidin (SIGMA-AL-
DRICH).
Side population (SP) assay
Side population (SP) analysis was performed as described
previously with some modifications [34,35]. The cells were stained
with Hoechst33342 dye (Lonza, Walkersville, MD, USA) at final
concentrations of 5 mg/ML for LHK2 and SW480 cells and 2 mg/
ml for MCF7 cells with or without Verapamil (SIGMA-
ALDRICH), an inhibitor of ABC transporters, at the concentra-
tion of 75 mM. The cells were incubated at 37uC for 90 min with
continuous shaking. Stained cells were analyzed by a FACS Aria II
(BD Biosciences, San Jose, CA, USA). The Hoechst 33342 dye was
excited at 357 nm and its fluorescence was analyzed using dual
wavelengths (blue, 402–446 nm; red, 650–670 nm).
RNA extraction and reverse transcription-PCR analysis
Isolation of RNA and RT-PCR analysis were performed as
described previously [36]. Human Multiple Tissue cDNA Panels I
and II (TAKARA BIO INC., Otsu, JAPAN) and the Human Fetal
Multiple Tissue cDNA Panel (TAKARA BIO INC.) were used as
templates of normal adult and fetal tissue cDNA. PCR amplifi-
cation was performed in 20 ml of PCR mixture containing 1 ml of
cDNA mixture, 0.5 ml of Taq DNA polymerase (QIAGEN) and
4 pmol of primers. The PCR mixture was initially incubated at
94uC for 2 min, followed by 35 cycles of denaturation at 94uC for
15 sec, annealing at 58uC for 30 sec, and extension at 72uC for
30 sec. Primer pairs used for RT-PCR analysis were 59-
TGGAGAAGGAGAAGCTGGAGCAAAA-39 and 59-GGCA-
GATGGTCGTTTGGCTGAATA-39 for POU5F1 with an ex-
pected PCR product size of 163 bps, 59- GCTGAGATGCCT-
CACACGGAG-39 and 59- TCTGTTTCTTGACCGGGACCT-
TGTC-39 for NANOG with an expected PCR product size of
161 bps, 59- TGTGTGACCAGACAAAACACAG -39 and 59-
GTTGGGCTCAGACTCCATGT -39 for SMCP with an expect-
ed PCR product size of 249 bps, 59- TCACTAGGCTGCTGAG-
GAAGA -39 and 59- CTGGGCAGCATTTACTGTGT -39 for
SMCP-variant1 with an expected PCR product size of 152 bps, 59-
TTCAGGaAGCGTGTGACAGT -39 and 59- CTGGGCAG-
CATTTACTGTGT -39 for SMCP-variant2 with an expected PCR
product size of 624 bps, and 59-ACCACAGTCCATGCCAT-
CAC-39 and 59-TCCACCACCCTGTTGCTGTA-39 for glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) with an expected product
size of 452 bps. GAPDH was used as an internal control. PCR
amplification for SOX2 was performed with PrimeSTAR HS DNA
polymerase (TAKARA BIO INC.). The PCR mixture was initially
incubated at 98uC for 2 minutes, followed by 35 cycles of
denaturation at 98uC for 15 seconds, and annealing and extension
at 68uC for 30 seconds. SOX2 expression was detected using sense
primer 59-CATGATGGAGACGGAGCTGA-39 and antisense
primer 59-ACCCCGCTCGCCATGCTATT-39 with an expected
PCR product size of 420 bp.
Quantitative real-time PCR analysis
Quantitative real-time PCR was performed using the ABI
PRISM 7000 Sequence Detection System (Applied Biosystems,
Foster City, CA) according to the manufacturer’s protocol. SOX2
primer and probe was designed by the manufacturer (TaqMan
Gene expression assays; Applied Biosystems). Thermal cycling was
performed using 40 cycles of 95uC for 15 seconds followed by
60uC for 1 min. Each experiment was done in triplicate, and
normalized to the GAPDH gene as an internal control.
Microarray analyses
We used the commercially available amino-allyl RNA ampli-
fication Kit ver,2 (High Yield Type) (SIGMA-ALDRICH).
Purified total RNA (3 mg) was reverse-transcribed to generate
double-stranded cDNA using an oligo dT T7 promoter primer
and reverse transcriptase. Next, cRNA was synthesized using T7
RNA polymerase, which simultaneously incorporated Cy3- or
Cy5-labeled cytidine triphosphate. During this process, the
samples of SP cells were labeled with Cy5, whereas the non-SP
cells were labeled with Cy3 as control cells. Quality of the cRNA
was again checked using the Nano Drop. Cy3-labeled cRNA and
Cy5-labeled cRNA were combined and then fragmented in a
hybridization cocktail (SIGMA-ALDRICH). Then the labeled
cRNAs were hybridized to a 60-mer probe oligonucleotide
microarray (Panorama Human Micro Array, SIGMA-AL-
DRICH) and incubated for 20 h ours at 50uC. The fluorescent
intensities were determined by a Genepix 4000B Microarray
Scanner (Axon, US). We performed the samples of SP cells were
labeled with Cy3 whereas the non-SP cells were labeled with Cy5.
Microarray raw data and processed data have been deposited in a
ArrayExpress database (http://www.ebi.ac.uk/arrayexpress/, Ac-
cession Number: E-MEXP-3913).
SMCP in Cancer Stem Cells
PLOS ONE | www.plosone.org 2 November 2013 | Volume 8 | Issue 11 | e69095
59-Rapid amplification of cDNA ends (59-RACE) and
39-RACE
59 Rapid amplification of cDNA ends (59-RACE) and 39-RACE
were carried out using total RNA isolated from Lc817 cells to
identify the transcriptional start site of the SMCP gene in the
cancer cell lines, following the protocol of manufacturer
(TAKARA BIO INC.). Briefly, 1 mg of total RNA was utilized
to generate either 59 or 39 RACE Ready cDNA products with
specific primers and reagents provided by the kit in the presence of
Moloney Murine Leukemia Virus (MMLV) reverse transcriptase.
Generation of the 59-RACE fragment was performed as described
in the protocol. In brief, 50 ml PCR reaction mixture consisting of
2.5 ml of 59-RACE-Ready cDNA, 5 ml of 106Universal Primer A
Mix (UPM), 1 ml of 10 mM Gene Specific Primer 1 (GSP1) and
41.5 ml of Master Mix (TAKARA BIO INC.) was prepared.
Positive and negative controls were prepared according to the
protocol of the manufacturer. GSP1 primer, 59- ATGGCCC-
CAGGGACTTCTTCTTTGT-39, was designed on the basis of
nucleotide sequences of SMCP CDS. Nested PCR reaction was
done by using diluted 1st PCR production, 1 ml nested universal
primer A (NUP) and 1 ml nested GSP1 primer, located upstream
of the GSP1 primer, 59-TGGCCTGGACTCATTTTGTG-
GGCTA-39, instead of the UPM primer and GSP1 primer. In
order to generate the 39 region fragment, 39-RACE was performed
by using a 50 ml PCR reaction mixture cosisting of 2.5 ml of 59-
RACE-Ready cDNA, 5 ml of 106UPM, 1 ml of 10 uM GSP2, 59-
CTGTGGTTTGGAGACCAAGCCTGAA-39, and 41.5 ml of
master mix. In nested PCR, 1 ml nested GSP2, 59- ATG-
GAGTCTGAGCCCAACTCACCGCAAA-39, was used. All
PCR products were purified and sequences were confirmed by
DNA sequencing.
Plasmid construct
The cDNA of human SMCP CDS was isolated from a human
testis cDNA library (TAKARA BIO INC.) by PCR, meanwhile
splicing variant2 was isolated from lung small cell carcinoma cell
line Lc817 by PCR. The SMCP CDS and splicing variant2 was
constructed into a pcDNA3.1(+) vector (Life Technologies,
Carlsbad, CA, USA), respectively.
Western blotting
Western blotting was performed as described previously [37].
Briefly, HEK293T cells were transfected with SMCP CDS
plasmid and splicing variant2 plasmid and then lysed in 1 mL of
SDS sample buffer. Anti-SMCP rabbit polyclonal antibody
(custum ordered, Life Technologies) was used at 200-times
dilution. Anti-b-Actin mouse monoclonal antibody (Sigma, St.
Louis, MO, USA) was used at 2000-times dilution.
Mice and xenograft transplantation
Non-obese diabetic-severe combined immunodeficient (NOD/
SCID) mice were purchased from Sankyo Laboratory Co. Ltd.
(Tsukuba, Japan). Studies were performed with approval of the
Animal Experiment Ethics Committee of Sapporo Medical
University (Sapporo, Japan).
Various numbers of SP and non-SP cells or LHK2-SMCP
and LHK2-Mock cells were suspended in a PBS and Matrigel
(BD Biosciences) mixture and transplanted to NOD/SCID mice
(female, 4–6 wk of age) under anesthesia. SP and non-SP cells or
LHK2-SMCP and LHK2-Mock cells were implanted into the
s.c. space on the left and right sides of the back of recipient
mice, respectively. Tumor formation was observed weekly for
10–13 weeks. The transplantation assays were performed in
accordance with institutional guidelines for the use of laboratory
animals.
Generation of GFP-SMCP cell line
The cDNA of human SMCP was isolated from a human testis
cDNA library (TAKARA BIO INC.) by PCR. The full-length
SMCP was constructed into a pcDNA3.1 (+) vector (Life
Technologies, Grand Island, NY, USA) fused with green
fluorescent protein (GFP) gene. LHK2 cells were transfected with
SMCP-GFP fusion expression plasmid by Lipofectamine 2000
(Life Technologies) and cultured in DMEM supplemented with
10% of FBS and 800 mg/mL Geneticin (Life Technologies).
Generation of stable cell line overexpressing SMCP
Introduction of DNA into LHK2 cells was performed by a
retrovirus-mediated method [33]. Briefly, the culture supernatant
of PLAT-A cells transduced with the pMXs-based retrovirus
vectors containing FLAG-epitope-tagged SMCP, was added onto
LHK2 cells in the presence of 8 mg/mL of polybrene (SIGMA-
ALDRICH) for 48 hrs. Two days later, the medium was replaced
with a fresh medium containing 1 mg/ml puromycin for LHK2
cells to select the infected cells. The mRNA expression of SMCP in
the puromycin-resistant sub-line was confirmed by RT-PCR.
Small interfering RNA transfection
SMCP small interfering RNA (siRNA) duplexes were designed
and synthesized using the BLOCK-it RNAi designer system (Life
Technologies). The oligonucleotide encoding SMCP siRNA1 was
59- CCCTTAACATGGAGTCTGAGCCCAA -39, and that
encoding siRNA2 was 59- GCAATCAATGCTGCCCACCA-
CAGCA -39. Cells were seeded at 50% confluence, and
transfections were carried out using Lipofectamine RNAiMAX
(Life Technologies) in Opti-MEM according to the manufacturer’s
instructions.
Confocal imaging
LHK2-GFP-SMCP cells were seeded on glass coverslips for
24 hr. The cells were then fixed with 4% paraformaldehyde,
permeabilized with 0.1% Triton X-100, and then blocked with
10% goat serum for 40 min. The cells were first stained with
MitoTracker Red 580 Dye (Life Technologies) for detecting
mitochondria at RT for 20 min and washed. Following this, they
were stained with DAPI (Life Technologies) at RT for 5 min and
mounted. Each sample was visualized using an LSM510 META
ConfoCor3 (Zeiss, Oberkochen, Germany), and images were
captured and analyzed using the Zeiss LSM Image Browser
(Zeiss).
Statistical analysis
Data are presented as means 6 SD. Differences in variables
were assessed using Student’s t-test. P,0.05 was considered
significant.
Results
Isolation of CSCs/CICs as SP cells in human lung, breast
and colon carcinoma cell lines
SP cells derived from LHK2, SW480 and MCF7 cells are
enriched with CSCs/CICs [35,38,39]. We therefore isolated SP
cells from LHK2, SW480 and MCF7 cells as CSC/CIC sources.
The cells were stained with Hoechst 33342 dye and analyzed with
a FACS Aria II flow cytomerter. The rations in LHK2, SW480
and MCF7 cells of SP cells were 1.3%, 1.5% and 0.5%,
SMCP in Cancer Stem Cells
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Figure 1. Isolation of a novel CSC/CIC molecule, SMCP. A. Isolation of SP cells from LHK2, MCF7 and SW480 cells. Lung (LHK2), colon
(SW480) and breast (MCF7) cancer cells were stained with Hoechst33342 dye in the absence (upper panel) or presence (lower panel) of verapamil. All
cell lines were analyzed by a cell sorter. B. Expression profiles of stem cell markers in SP cells and MP cells. Expression of stem cell markers
(SOX2, POU5F1 and NANOG) in SP cells and MP cells derived from LHK2, SW480 and MCF7 cells was determined. GAPDH was used as an internal
positive control. C. Quantitative real-time PCR analysis of SOX2 mRNA expression in SP and MP cells. The MP cells were used for the
control, which was set as 1.0. Data are expressed as mean + SD of relative values compared to MP cells. D. Expression of SMCP in SP and MP
cells. Expression of SMCP in SP cells and MP cells derived from LHK2, SW480 and MCF7 cells was determined. E. SMCP is localized in
mitochondria. LHK2 cells transfered with GFP-fused SMCP gene were fixed and stained with Mitotracker Red followed by DAPI and then visualized
by laser confocal microscopy (Magnification,6200). Green indicates GFP-fused SMCP. Red indicates mitochondria. Blue indicates nucleus.
doi:10.1371/journal.pone.0069095.g001
SMCP in Cancer Stem Cells
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respectively (Figure 1A). Greater tumor-initiating ability of SP cells
was confirmed by injecting NOD/SCID mice with the cells
(Table 1) [38]. To address the expression levels of stem cell
markers in SP cells, we performed RT-PCR analysis. SOX2,
POU5F1 and NANOG were expressed in SP cells derived from
LHK2, SW480 and MCF7 cells at higher levels than those in MP
cells (Figure 1B). Moreover, we evaluated three mRNA transcripts
with quantitative real-time PCR. As shown in figure 1C, SOX2
mRNA was significantly overexpressed in SP cells compared with
MP cells. The results indicated that these SP cells had molecular
properties similar to those of iPS cells [40].
Sperm mitochondria-associated cysteine-rich protein
(SMCP) is preferentially expressed in SP cells
To address the molecular mechanism of SP cells, we performed
gene chip microarray screening using total RNA from LHK2 SP
cells and LHK2 MP cells (Table S1). We found that SMCP gene
oligo reactive mRNA was overexpressed in LHK2 SP cells
compared with the expression level in LHK2 MP cells. RT-PCR
analysis revealed that SMCP mRNA was overexpressed in SP cells
derived from LHK2, SW480 and MCF7 cells compared to the
expression levels in MP cells (Figure 1D). Since the SMCP protein
was reported to be expressed in sperm mitochondria [41], the
cellular localization of SMCP in cancer cells was investigated using
a GFP-fused SMCP gene. Co-localization of GFP-fused SMCP
and a mitochondria marker (MitoTracker) was observed in LHK2
cells with overexpressed GFP-SMCP gene, indicating that
ectopically expressed SMCP protein is also localized in mitochon-
dria (Figure 1E).
Expression profiles of SMCP in normal tissues and cancer
cells
RT-PCR analysis was performed to determine the expression of
SMCP in human fetal and adult normal tissues and in cancer cells.
SMCP mRNA was expressed only in the testis at a high level
among human adult tissues (Figure 2A). SMCP mRNA was
detected in all cancer cells tested in this study, including renal cell
carcinoma cells (Caki-1, ACHN, SMKT-R1, SMKTR-2,
SMKTR-3 and SMKTR-4), lung squamous cell carcinoma cells
(Sq-1), lung small cell carcinoma cells (Lc817), lung large cell
carcinoma cells (86-2 and Lu99), lung adenocarcinoma cells (1-87
and A549) and pancreas carcinoma cells (HPC3) (Figure 2B).
SMCP mRNA was preferentially expressed in primary lung
cancerous tissues in 5 cases (2 adenocarcinomas, 2 squamous cell
carcinomas and 1 large cell carcinoma) than those in adjacent
normal counterpart lung tissues (Figure 2C).
Novel SMCP splicing variant2 is the dominant form in
cancer cells
The SMCP transcript is composed of two exons (Variant 1,
Figure 2D upper panel), and we tried to detect the SMCP
transcript by quantitative PCR (qPCR) using a probe designed at
the junction of exon 1 and exon 2. We detected SMCP mRNA in
the testis tissue, but we did not detect SMCP mRNA in any of the
cancer cells by qPCR. We therefore hypothesized that the
transcript of SMCP in cancer cells was different from that in the
testis. To address the structure of SMCP mRNA, we performed 59
RACE and 39 RACE. The cDNA template used was prepared
from the Lc817 cell line, which showed a high level of SMCP
transcript (Figure 2B). The 59 RACE PCR amplification revealed
that the SMCP mRNA from Lc817 is composed of only one exon
that is overlapped with exon 2 with 59 extension (termed SMCP
variant 2) and shares coding sequence (CDS) (Figure 2D). We
therefore analyzed the SMCP mRNAs in testis and cancer cells
using a mixture of SMCP variant1-specific primer (F1) and SMCP
variant2-specific primer (F2), and we found that SMCP vt1 is
expressed in the testis and that SMCP vt2 is expressed in cancer
cells (Figure 2E). We could detect a specific band with anti-SMCP
polyclonal antibody in the HEK293T cell line transfected with
expression vectors of both variant2 and variant1 CDS (Fig. 2F),
suggesting that both variant1 and variant2 have the same protein
products. We therefore used CDS expression constract for further
analyze of SMCP functions.
SMCP has a role in tumor-initiating ability
Since SMCP is preferentially expressed in SP cells, we further
analyzed the function of SMCP using SMCP-overexpressing cells.
SMCP cDNA was stably transduced into LHK2 cells, and its
expression was confirmed by RT-PCR (Figure 3A). A tumor was
initiated by 16102 LHK2-SMCP cells in 1 of 5 mice, and tumors
were initiated by 16103 and 16104 LHK2-SMCP cells in 3 of 5
Table 1. Tumor-initiating ability of SP and MP cells.
MCF7 Cell numbers of injection into NOD/SCID mice
Day 91 post injection 1.56101 1.56102 1.56103 1.56104
SP cells Incidence 1/1 1/1 1/1 n.d.
Volumes (mm3) 0.5 683.6 288.8 -
MP cells Incidence 0/1 0/1 1/1 1/1
Volumes (mm3) - - 165.5 691.9
SW480 Cell numbers of injection into NOD/SCID mice
Day 42 post injection 1.06101 1.06102 1.06103 1.06104
SP cells Incidence 1/3 1/3 3/3 3/3
Volumes (mm3) 40 720 12256571.7 716762020
MP cells Incidence 0/3 1/3 3/3 3/3
Volumes (mm3) - 50 2816129 278961910
Incidence indicates the number of tumor formation/number of injections.
Tumor volumes are mean6S.D.
doi:10.1371/journal.pone.0069095.t001
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Figure 2. Expression profiles of SMCP and identification of a novel variant form of SMCP. A. SMCP expression profiles in normal
human organs. SMCP mRNA expression in normal tissues (heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus,
prostate, testis, ovary, small intestine, leukocyte, colon, stomach and bone marrow) was investigated by RT-PCR. cDNAs were obtained from TAKARA
BIO INC. (Human Multiple Tissue cDNA Panels I and II). GAPDH was used as an internal positive control. B. SMCP expression profiles in human
cancer cells. SMCP mRNA expression in lung cancer line cells (Sq-1, Lc817, 86-2, Lu99, 1-87, A549), renal cancer line cells (Caki-1, ACHN, SMKTR1,
SMKTR2, SMKTR3, SMKTR4) and pancreas cancer line cell (HPC3) was investigated by RT-PCR. cDNAs were generated by total RNAs derived from cell
lines. GAPDH was used as an internal positive control. C. SMCP expression profiles in human lung cancer tissues. SMCP mRNA expression in
human lung cancer tissues was investigated by RT-PCR. #1 and #2 are adenocarcinoma cases. #3 and #4 are squamous cell carcinoma cases. #5 is
a large cell carcinoma case. T indicates lung cancer tissue. N indicates adjacent lung normal tissue. GAPDH was used as an internal positive control. D.
Schema of novel variant form of SMCP. SMCP wild type (variant 1) is composed of exon 1 and exon 2. The novel isoform of SMCP (variant 2) has
only one exon with a 59 terminal additional extension. E. Expression profiles of SMCP variant 1 and variant 2 in the testis and cancer cells.
SMCP mRNA expression was investigated by RT-PCR using an F1 and F2 mixture primer as a forward primer and R1 primer as a reverse primer in testis
and cancer cells. Variant 1 was a 152-bp PCR product, and variant 2 was a 624-bp PCR product. F. Expression of SMCP protein. Detection of SMCP
protein in HEK293T cells transfected with expression vectors of variant1 CDS and variant2 as assessed by Western blot analysis with polyclonal SMCP
antibody. Beta-actin was used as a protein loading control.
doi:10.1371/journal.pone.0069095.g002
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mice and 5 of 5 mice, respectively. On the other hand, a tumor
was initiated by 16104 LHK2-Mock cells in 3 of 5 mice, and no
tumor initiation was observed with 16102 or 16103 LHK2-Mock
injection (Table 2). Furthermore, the growth of tumors derived
from LHK2-SMCP cells was significantly faster than that of
tumors derived from LHK2-Mock cells (Figure 3B and 3C).
Downregulation of SMCP by siRNA abrogates tumor-
initiating ability of wild-type and SP cells of lung cancer cells
The results obtained by using SMCP-overexpressing cells
suggested that SMCP has a role in tumor initiation, and we
therefore performed a gene knockdown study using siRNAs. We
designed two different siRNAs and confirmed gene knockdown by
RT-PCR using SMCP siRNA-transfected LHK2 cells (Figure 4A).
To investigate the tumor-initiating ability of SMCP knockdown
cells, we injected SMCP siRNA-transfected LHK2, Lc817 and
A549 cells into NOD/SCID mice. Tumor growth was significantly
suppressed in mice injected with SMCP siRNA1 and siRNA2-
transfected LHK2, Lc817 and A549cells compared to that in mice
injected with control siRNA-transfected LHK2 cells (Figure 4B
and 4C and table 3).
Since SMCP was preferentially expressed in SP cells, we
therefore performed gene knockdown using SP cells derived from
wild type LHK2 cells. Two hundred siRNA-transfected LHK2 SP
Figure 3. SMCP has a role in the tumor-initiating ability in LHK2 lung adenocarcinoma cells. A. Expression of SMCP in SMCP-
overexpressed LHK2 cells. Expression of SMCP in LHK2-SMCP cells was confirmed by RT-PCR. B. Representative picture of tumors injected
with SMCP-overexpressed LHK2 cells. C. Tumor growth of LHK2-SMCP cells and LHK2-Mock cells. One6103 and 16104 of LHK2-SMCP
cells and LHK2-Mock cells were injected into NOD/SCID mice subcutaneously. Data are means + SD. Asterisks represents statistical significant
difference. Student’s t-test. P,0.05.
doi:10.1371/journal.pone.0069095.g003
Table 2. Tumor-initiating ability of LHK2-SMCP and LHK2-mock.
Cell numbers of injection into NOD/SCID mice
Day 35 post injection 16101 16102 16103 16104
LHK2-SMCP Incidence 0/5 1/5 3/5 5/5
Volumes (mm3) - 4.0 57.3643.9 436.36386.2*
LHK2-mock Incidence 0/5 0/5 0/5 3/5
Volumes (mm3) - - - 4.8367.5
Incidence indicates the number of tumor formation/number of injections.
Tumor volumes are mean6S.D.
*P,0.01, compared with tumor volumes of 16104 Mock cells.
LHK2-SMCP, SMCP-overexpressing LHK2 cells; LHK2-mock, mock-transfected cells.
doi:10.1371/journal.pone.0069095.t002
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cells were injected into the backs of NOD/SCID mice. Control
siRNA-transfected LHK2 SP cells initiated tumors, whereas
SMCP siRNA-transfected LHK2 SP cells did not initiate tumors
(Figure 5). Taken together, these results indicate that SMCP has a
role in the tumor-initiating ability of CSCs/CICs.
Discussion
In this study, we investigated the gene expression profile of SP
cells derived from LHK2 lung adenocarcinoma cells. The
existence of CSCs/CICs has been discussed widely over the past
decade [40,41][42]. The concept of stem cell-like tumor cells is
intriguing; however, identification and isolation of such cells is
difficult. Stem cells are identified by expression of surface markers
or functional markers such as ABC transporters or ALDH, and
clonogenic potential and capacity to regenerate tumors of the
identified subset of tumor cells are subsequently demonstrated
[42]. Although the field of CSC/CIC biology is a relatively new
field, continued elucidation of the features of these cells holds
promise for the development of novel patient therapies [42][43].
Moreover, evidence supporting the existence of CSCs/CICs in
various solid tumors has been obtained; however, a definite CSC/
Figure 4. SMCP knockdown abrogates tumor initiation of LHK2 cells. A. Downregulation of SMCP expression in LHK2 cells
transfected with siRNA. B. Representative picture of tumors injected with SMCP knockdown LHK2 cells. C. Tumor growth of LHK2,
A549 and Lc817 cells transfected with SMCP siRNAs. Two6105 LHK2 cells transfected with control siRNA or SMCP siRNA 1 and 2 were injected
into NOD/SCID mice subcutaneously. One6104 A549 cells transfected with control siRNA or SMCP siRNA2 were injected into NOD/SCID mice
subcutaneously. One6104 Lc817 cells transfected with control siRNA or SMCP siRNA2 were injected into NOD/SCID mice subcutaneously. Data are
means + SD. Asterisks represents statistical significant difference. Student’s t-test. P,0.05.
doi:10.1371/journal.pone.0069095.g004
SMCP in Cancer Stem Cells
PLOS ONE | www.plosone.org 8 November 2013 | Volume 8 | Issue 11 | e69095
CIC marker has not yet been established. Attempts to enrich
CSCs/CICs by using SP analysis have been made in several
studies [10,35,38,44–47]. In this study, we succeeded in isolating
SP cells from LHK2 lung carcinoma cells, SW480 colon
carcinoma cells and MCF7 breast carcinoma cells. SP cells
exhibited greater tumor-initiating ability and higher expression
levels of iPS cell-related genes (SOX2, POU5F1 and NANOG),
indicating that SP cells derived from LHK2, SW480 and MCF7
cells are enriched with CSCs/CICs and are a reasonable source
for further research.
Gene expression profiling using cDNA microarrays and RT-
PCR analysis revealed that the sperm-related gene SMCP is
ectopically expressed in SP cells derived from LHK2, SW480 and
MCF7 cells. Several molecular mechanisms of cancer stem cells
have been described. Weinberg’s group described that breast
cancer stem cells also have epithelial-mesenchimal transition
(EMT) phenotypes [48]. However, we did not detect any EMT
related genes by cDNA microarray. SOX2 have been showed to
be related to lung carcinogenesis, and we also found that SOX2
was overexpressed in LHK2 SP cells [49] [50] [38]. Other report
Table 3. Tumor-initiating ability of SMCP siRNA and Control siRNA.
LHK2 Cell numbers of injection into NOD/SCID mice
Day 35 post injection Contorl siRNA SMCP siRNA1 SMCP siRNA2
26105 Incidence 6/6 2/5 0/5
Volumes (mm3) 27.8615.7 0.961.7* -
Lc817 Cell numbers of injection into NOD/SCID mice
Day 28 post injection Contorl siRNA SMCP siRNA1 SMCP siRNA2
16104 Incidence 3/4 - 0/4
Volumes (mm3) 541.16299.2 - 0.060.0{
A549 Cell numbers of injection into NOD/SCID mice
Day 28 post injection Contorl siRNA SMCP siRNA1 SMCP siRNA2
16104 Incidence 4/4 - 0/4
Volumes (mm3) 176.66147.4 - 0.060.0{
Incidence indicates the number of tumor formation/number of injections.
Tumor volumes are mean6S.D.
*P,0.01, compared with tumor volumes of 26105 Control siRNA cells.
{P,0.05, compared with tumor volumes of 16104 Control siRNA cells.
doi:10.1371/journal.pone.0069095.t003
Figure 5. SMCP knockdown abrogates tumor initiation of LHK2 SP cells. LHK2 SP cells were isolated and seeded onto a 24-well plate. SMCP
siRNA was transfected into LHK2 SP cells. Two days after transfection, LHK2 SP cells were injected into NOD/SCID mice. Data are means + SD. Asterisks
represents statistical significant difference. Student’s t-test. P,0.05.
doi:10.1371/journal.pone.0069095.g005
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showed that cytosolic glycine decarboxylase was related to the
tumor-initiating ability of lung cancers [9]. However, this is the
first report that mitochondria-related gene has tumorigenic
potential.
The product of the SMCP gene localizes to the capsule
associated with the mitochondrial outer membranes and is thought
to function in the organization and stabilization of the crescent
structure of the sperm’s mitochondrial sheath [41]. Sperm
mitochondria differ in morphology and subcellular localization
from those of somatic cells. They are elongated, flattened, and
arranged circumferentially to form a helical coiled sheath in the
midpiece of the sperm flagellum. In this study, we investigated the
distributions of SMCP protein, and we found that GFP-fused
SMCP protein is expressed in the mitochondria of lung carcinoma
cells. Since SMCP is expressed in the testis and cancer cells,
SMCP is a novel cancer-testis (CT) gene [51]. The testis is also an
immune-privileged site [52]. Therefore, CT antigens are highly
immunogenic and are promising targets for cancer immunother-
apy [53–55]. Some cancer–testis antigens have been isolated by
analyzing a testis cDNA expression library with cancer patients’
sera [54]. Although SMCP has not been reported by screening
using cancer patients’ sera, SMCP was reported to be recognized
by sera from rats immunized by sperm [56]. Thus, SMCP might
be immunogenic to the humoral immune system. Indeed, we
could detect anti-SMCP antibody in cancer patients’ sera by an
ELISA assay using SMCP recombinant protein (unpublished
data). Anti-SMCP antibody might therefore be a new useful
biomarker for detection of CSCs/CICs that is related to prognosis
of cancer patients.
RACE and RT-PCR analysis revealed that the transcript of
SMCP in CSCs/CICs was a variant form (SMCP vt2). SMCP
vt2 lacks exon 1 and has only one exon 2 which has 889 base
pair extension to the 59-end. Since wild-type SMCP (SMCP vt1)
and SMCP vt2 share the same coding sequence, the SMCP
protein structures in CSCs/CICs and the testis should be same.
However, the transcriptional start point of SMCP vt2 is
approximately 6000 base pairs downstream of the transcrip-
tional start point of SMCP vt1. Thus, the transcription factor
and promoter that are responsible for the transcription of
SMCP vt 2 should be different from those of SMCP vt 1.
Further molecular analysis is needed.
In this study, overexpression of SMCP enhanced tumorigenicity
in vivo. Moreover, transient knockdown of SMCP mRNA by
SMCP-specific siRNA completely abrogated the tumorigenicity of
LHK2 bulk cells and even SP cells. These observations indicate
that SMCP has a pivotal role in tumorigenicity of lung cancer;
however, its exact molecular mechanisms are still elusive.
In summary, we identified a novel variant form of the sperm-
specific antigen SMCP that is expressed in CSCs/CICs and
showed that SMCP plays a role in lung CSC/CIC tumorigenicity.
Since SMCP is expressed in cancer tissues but not in normal tissues
except for the testis, SMCP might be a novel CSC/CIC marker
and a promising and potential target of CSC/CIC-targeting
therapy.
Supporting Information
Table S1 Summary of upregulated genes in LHK2 SP
cells. The summary of upregulated genes in SP cells derived from
LHK2 cells. Cy5/Cy3: SP cells were labeled with Cy5 and MP
cells were labeled with Cy3. Cy3/Cy5: SP cells were labeled with
Cy3 and MP cells were labeled with Cy5.
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